Maternal treatment with sodium butyrate reduces the development of autism-like traits in mice offspring

Biomed Pharmacother. 2022 Dec:156:113870. doi: 10.1016/j.biopha.2022.113870. Epub 2022 Oct 21.

Abstract

Several studies indicate a relationship between maternal gut microbiota alteration and increased risk of autism spectrum disorders (ASD) in offspring. The possibility of compensating for such metabolic dysfunction at a very early stage of disease via maternal treatment has not been enough explored. Here, we examined in BTBR mouse model of ASD the effect of maternal treatment with the gut microbial metabolite butyrate (BUT) on the behavioral and synaptic plasticity deficits in juvenile and adult offspring. We show that BUT treatment of BTBR dams rescues the social and partially the repetitive behavior deficits in the offspring. In addition, maternal BUT implementation prevents the cerebellar cortex hypertrophy as well as the Purkinje cells firing and long-term synaptic plasticity deficits in BTBR mice. Our results demonstrate, for the first time, that maternal BUT treatment can improve ASD-like symptoms in offspring thus providing new directions for the early treatment of neurodevelopmental disorders.

Keywords: Autism spectrum disorder; Behavior; Cerebellum; Parallel fiber; Purkinje cells; Sodium butyrate.

MeSH terms

  • Animals
  • Autism Spectrum Disorder* / drug therapy
  • Autism Spectrum Disorder* / metabolism
  • Autism Spectrum Disorder* / prevention & control
  • Autistic Disorder* / drug therapy
  • Behavior, Animal
  • Butyric Acid / pharmacology
  • Disease Models, Animal
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Social Behavior

Substances

  • Butyric Acid